SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
78,400
-600 (-0.76%)
At close: Aug 3, 2026

SK Biopharmaceuticals Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
348,808266,950240,738-32,883-139,43164,846
Depreciation & Amortization
16,24916,94717,42815,31712,98411,642
Loss (Gain) From Sale of Assets
194.8194.81-171.0218.7211.283.02
Asset Writedown & Restructuring Costs
-597.33-597.33-6,808172.96-
Loss (Gain) From Sale of Investments
-7,4752,7571,396-12,2432,858-2,208
Loss (Gain) on Equity Investments
32,76434,30731,25311,53514,92734,544
Stock-Based Compensation
-662.723,6337,5113,23360.66416.71
Other Operating Activities
-105,316-111,576-170,591-10,34514,161-132,402
Change in Accounts Receivable
-105,252-58,344-37,064-52,456-13,169-41,610
Change in Inventory
22,16010,880-8,593-13,708-38,693-29,459
Change in Accounts Payable
-9,6166,036940.7-20,7116,965607.69
Change in Other Net Operating Assets
-24,2915,14412,05311,232-20,767748.38
Operating Cash Flow
166,965176,33494,900-94,201-159,920-92,872
Operating Cash Flow Growth
67.36%85.81%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-8,186-6,892-1,395-2,385-4,911-4,316
Sale of Property, Plant & Equipment
-----11.24
Cash Acquisitions
---31,043--
Sale (Purchase) of Intangibles
-23,290-22,119-10,726-864.17-1,050-1,676
Investment in Securities
-6,380-4,3673,506198,587-89,691265,618
Other Investing Activities
-3,054-2,068-2,340-1,104-10.78-639.56
Investing Cash Flow
-40,972-35,420-10,941225,273-95,714258,971

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-6.94100,000---
Long-Term Debt Issued
----141,751-
Total Debt Issued
6.946.94100,000-141,751-
Short-Term Debt Repaid
--50,007-50,000---
Long-Term Debt Repaid
--106,678-54,498-5,575-5,477-4,827
Total Debt Repaid
-81,890-156,685-104,498-5,575-5,477-4,827
Net Debt Issued (Repaid)
-81,883-156,678-4,498-5,575136,274-4,827
Other Financing Activities
-6,284-0.3812,198-1,360180.69
Financing Cash Flow
-88,167-156,678-4,4986,623134,914-4,646

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
4,219727.943,646-2,054-1,1435,135
Miscellaneous Cash Flow Adjustments
-0----0
Net Cash Flow
42,046-15,03683,107135,640-121,863166,589

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
158,779169,44293,505-96,586-164,831-97,188
Free Cash Flow Growth
61.43%81.21%----
Free Cash Flow Margin
20.09%23.97%17.08%-27.22%-66.96%-23.21%
Free Cash Flow Per Share
2026.782163.641193.98-1233.34-2104.77-1241.01
Levered Free Cash Flow
75,879112,02833,476-54,562-108,21051,274
Unlevered Free Cash Flow
79,913116,83440,152-49,387-105,88851,865

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
5,1136,4449,4998,1423,488844.19
Cash Income Tax Paid
20,39220,03512,1548,1264,6816,160
Change in Working Capital
-116,999-36,283-32,663-75,643-65,664-69,713